Bio

Clinical Focus


  • Neurosurgery
  • Degenerative Spine Disease
  • Deep Brain Stimulation
  • Spinal Cord Stimulation for Chronic Pain
  • Brain Tumors
  • Spinal Stenosis
  • Parkinson's Disease
  • Essential Tremor
  • Epilepsy Surgery
  • Complex Regional Pain Syndromes
  • Trigeminal Neuralgia
  • Occipital Neuralgia
  • Spinal Fusion
  • Herniated Discs
  • Peripheral Nerve Stimulation for Pain
  • Meningioma
  • Movement Disorders
  • Stereotactic and Functional Neurosurgery

Academic Appointments


Administrative Appointments


  • Associate Director, Coulter-Case Translational Research Partnership, Case Western Reserve University (2008 - 2010)
  • Biomedical Innovation Fellow, Department of Biomedical Engineering, Case Western Reserve University (2008 - 2010)
  • Associate, Bioenterprise Cleveland OH (2008 - 2010)

Honors & Awards


  • Silver Kings Crown Award, Columbia University (1998)
  • Gold Kings Crown Award, Columbia University (1999)
  • Senior Marshall, Columbia University (1999)
  • Outstanding Student in Psychiatry Award, NEOMED (2004)
  • Medical Student Prize for Excellence in Neurology, American Academy of Neurology (2004)
  • Member, Alpha Omega Alpha (Honor Medical Society) (2004)
  • Fellow, Doximity (2013)
  • Socioeconomic Fellow, The Council of State Neurological Societies (2009-2010)

Boards, Advisory Committees, Professional Organizations


  • Member, American Association of Neurological Surgeons (2013 - Present)
  • Member, Congress of Neurological Surgeons (2014 - Present)
  • Member, North American Spine Society (2014 - Present)
  • Member, International Neuromodulation Society (2014 - Present)
  • Member, San Francisco Neurological Society (2014 - Present)
  • Member, Santa Clara County Medical Association (2013 - Present)
  • Member, North American Neuromodulation Society (2014 - Present)
  • Member, Alpha Omega Alpha (Medical Honor Society) (2004 - Present)
  • Member, Biomedical Engineering Society (2008 - Present)

Professional Education


  • BS, Columbia University New York, NY, Biomedical Engineering (1999)
  • MSE, University of Pennsylvania Philadelphia, PA, Biomedical Engineering (2000)
  • Medical Education:Northeastern Ohio Universities (2004) OH
  • Internship:Case Western Reserve University School of Medicine (2005) OH
  • Residency:Case Western Reserve University School of Medicine (2011) OH
  • Fellowship, Stanford University Stanford, CA, Stereotactic and Functional Neurosurgery (2012)

Research & Scholarship

Current Research and Scholarly Interests


Clinical Outcome Studies, Deep Brain Stimulation, Engineering and Medicine

Publications

Journal Articles


  • Deep brain stimulation surgical techniques. Handbook of clinical neurology Khan, F. R., Henderson, J. M. 2013; 116: 27-37

    Abstract

    Stereotactic techniques for placement of deep brain stimulation (DBS) electrodes have undergone continuous refinement since the introduction of human stereotaxis in the 1940s. Volumetric imaging techniques, including magnetic resonance imaging and computed tomography, have replaced ventriculography, and increasingly sophisticated computer systems now allow highly refined targeting of subcortical structures. This chapter reviews the underlying principles of stereotactic surgery, including imaging, targeting, and registration, and describes the surgical approach to DBS placement using both framed and frameless techniques.

    View details for DOI 10.1016/B978-0-444-53497-2.00003-6

    View details for PubMedID 24112882

  • Does Ganglionectomy Still Have a Role in the Era of Neuromodulation? WORLD NEUROSURGERY Khan, F. R., Henderson, J. M. 2012; 77 (2): 280-282

    View details for DOI 10.1016/j.wneu.2011.09.034

    View details for Web of Science ID 000303233800023

    View details for PubMedID 22120250

  • Teaching Neurosurgery in the 21st Century. AANS Neurosurgeon Hdeib, A. M., Khan, F. R., Hart, D. J., Miller, J. P. 2012; 21 (2)
  • Duplication of the pituitary gland associated with multiple blastogenesis defects: Duplication of the pituitary gland (DPG)-plus syndrome. Case report and review of literature. Surgical neurology international Manjila, S., Miller, E. A., Vadera, S., Goel, R. K., Khan, F. R., Crowe, C., Geertman, R. T. 2012; 3: 23-?

    Abstract

    Duplication of the pituitary gland (DPG) is a rare craniofacial developmental anomaly occurring during blastogenesis with postulated etiology such as incomplete twinning, teratogens, median cleft face syndrome or splitting of the notochord. The complex craniocaudal spectrum of blastogenesis defects associated with DPG is examined with an illustrative case.We report for the first time in the medical literature some unique associations with DPG, such as a clival encephalocele, third cerebral peduncle, duplicate odontoid process and a double tongue with independent volitional control. This patient also has the previously reported common associations such as duplicated sella, cleft palate, hypertelorism, callosal agenesis, hypothalamic enlargement, nasopharyngeal teratoma, fenestrated basilar artery and supernumerary teeth. This study also reviews 37 cases of DPG identified through MEDLINE literature search from 1880 to 2011. It provides a detailed analysis of the current case through physical examination and imaging.The authors propose that the developmental deformities associated with duplication of pituitary gland (DPG) occur as part of a developmental continuum, not as chance associations. Considering the fact that DPG is uniquely and certainly present throughout the spectrum of these blastogenesis defects, we suggest the term DPG-plus syndrome.

    View details for DOI 10.4103/2152-7806.92939

    View details for PubMedID 22439114

  • Pharmacological management of acromegaly: a current perspective NEUROSURGICAL FOCUS Manjila, S., Wu, O. C., Khan, F. R., Khan, M. M., Arafah, B. M., Selman, W. R. 2010; 29 (4)

    Abstract

    Acromegaly is a chronic disorder of enhanced growth hormone (GH) secretion and elevated insulin-like growth factor–I (IGF-I) levels, the most frequent cause of which is a pituitary adenoma. Persistently elevated GH and IGF-I levels lead to substantial morbidity and mortality. Treatment goals include complete removal of the tumor causing the disease, symptomatic relief, reduction of multisystem complications, and control of local mass effect. While transsphenoidal tumor resection is considered first-line treatment of patients in whom a surgical cure can be expected, pharmacological therapy is playing an increased role in the armamentarium against acromegaly in patients unsuitable for or refusing surgery, after failure of surgical treatment (inadequate resection, cavernous sinus invasion, or transcapsular intraarachnoid invasion), or in select cases as primary treatment. Three broad drug classes are available for the treatment of acromegaly: somatostatin analogs, dopamine agonists, and GH receptor antagonists. Somatostatin analogs are considered as the first-line pharmacological treatment of acromegaly, although efficacy varies among the different formulations. Octreotide long-acting release (LAR) appears to be more efficacious than lanreotide sustained release (SR). Lanreotide Autogel (ATG) has been shown to result in similar biological control as octreotide LAR, and there may be a benefit in switching from one to the other in some cases of treatment failure. The novel multireceptor somatostatin analog pasireotide, currently in Phase II clinical trials, also shows promise in the treatment of acromegaly. Dopamine agonists have been the earliest and most widely used agents in the treatment of acromegaly but have been found to be less effective than somatostatin analogs. In this class of drugs, cabergoline has shown greater efficacy and tolerability than bromocriptine. Dopamine agonists have the advantage of oral administration, resulting in increased use in select patient groups. Selective GH receptor antagonists, such as pegvisomant, act by blocking the effects of GH, resulting in decreased IGF-I production despite persistent elevation of GH serum levels. Thus far, tumor growth has not been a concern during pegvisomant therapy. However, combination treatment with somatostatin analogs may counteract these effects. The authors discuss the latest guidelines for biochemical cure and highlight the efficacy of combination therapy. In addition, the effects of pharmacological presurgical treatment on surgical outcome are explored.

    View details for DOI 10.3171/2010.7.FOCUS10168

    View details for Web of Science ID 000283802600015

    View details for PubMedID 20887124

Books and Book Chapters


  • Overview of Biomaterials and their use in Medical Devices Handbook of Materials for Medical Devices Drummond, C. K., Hdeib, A., Khan, F. R. ASM International.. 2002; 2nd : 18-35

Stanford Medicine Resources: